University of California spin out Redwood Bioscience, Inc. has been utilizing precision protein-chemical engineering to create optimized conjugate therapeutics. Leveraging site specifically modified carrier scaffolds, Redwood is focused on developing antibody drug conjugates having superior therapeutic index profiles and peptide-based products with extended drug half-lives and enhanced potency. The companys site specific protein modification platform provides control over cargo placement on a protein, cargo orientation, and stoichiometry, enabling the creation of conjugate libraries from which homogenous compounds can be selected. Redwood Bioscience is utilizing precision protein-chemical engineering to develop optimized and novel biotherapeutics. The Company's site specific modification technology overcomes the significant challenges associated with conjugating biologics to synthetic molecules to create homogenous hybrid biotherapeutics. Hybrid drugs offer advantages over single agents by providing the specificity and half-life benefits of biologics with the potency benefits of synthetic peptides and small molecules. Leveraging site specifically modified carrier scaffolds, Redwood is developing peptide therapeutics with improved serum half lives and antibody drug conjugates designed to have improved potency and reduced toxicity. Moreover, through "expanding the chemical space of protein drugs", Redwood is developing heterofunctional products with unique protein-chemical architectures. The Company is working with partners to enhance the value of their investments in existing programs and to jointly develop novel compounds. Redwood also is developing biotherapeutics for its own internal programs. In 2014, a partner to the Redwood efforts inarlier years - Catalent Pharma Solutions Inc. - acquired partner Redwood Bioscience Inc.with the latter becoming part of Catalents biologics business.
